EUVIMEDEUVIMED entdecken
Crossref

Effects of FECH Gene Polymorphisms and Serum Ferrochelatase Levels on Antituberculosis Drug‐Induced Liver Injury in China

Jingru Cheng, Nannan Wang, Ruina Chen, Hongqiu Pan, Lihuan Lu, Meiling Zhang, Xiaomin He, Honggang Yi, Shaowen Tang iD

Fundamental & Clinical Pharmacology · 2025

DOI: 10.1111/fcp.70034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, 2025. Verfasst von Jingru Cheng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Antitubercular Agents, Chemical and Drug Induced Liver Injury, Ferrochelatase, Polymorphism, Single Nucleotide. Die Arbeit nennt 35 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The pathogenic mechanism of antituberculosis drug‐induced liver injury (ATLI) has not been elucidated. This study aimed to investigate the effects of FECH genetic polymorphisms and serum ferrochelatase levels on ATLI in the Chinese population.

Methods

One case–control study was conducted to investigate the association between four SNPs in FECH gene and ATLI, while another was used to analyze the association of serum ferrochelatase levels at three different times with ATLI. Multivariate logistic regression model was used to screen potential risk factors for ATLI, and the results were expressed as odds ratios (ORs) with 95% confidence intervals (CIs). The area under receiver operating characteristic curve (AUC) was calculated to estimate the performance for distinguishing ATLI cases from controls.

Results

Serum ferrochelatase levels were lower in ATLI cases than in controls at the time of baseline test, the first test and the second test after initial treatment. A multivariate logistic regression model showed that SNP rs536560 in the FECH gene (OR = 2.063, 95%CI: 1.112–3.892, p = 0.023), baseline serum ferrochelatase level (OR = 3.162, 95%CI: 1.605–6.234, p = 0.001), and liver disease history (OR = 2.915, 95%CI: 1.301–6.461, p = 0.008) were the risk factors for ATLI. The ROC curves demonstrated that the model including the above three factors has strong discriminating ability (AUC = 0.709, 95%CI: 0.639–0.779, p < 0.0001).

Conclusions

This study is the first to explore the relationships between SNPs in the FECH gene, serum ferrochelatase levels, and ATLI in China, and SNP rs536560 in the FECH gene, baseline ferrochelatase level, and liver disease history may be associated with susceptibility to ATLI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antitubercular AgentsChemical and Drug Induced Liver InjuryFerrochelatasePolymorphism, Single NucleotideAdultFemaleHumansMaleMiddle AgedCase-Control StudiesChinaGenetic Predisposition to DiseaseRisk Factors

Stichwörter der Autor:innen

antituberculosis drug‐induced liver injuryferrochelatasegenetic polymorphismsmultivariate logistic regression modelserum levels

Substanzen

Antitubercular AgentsFerrochelataseFECH protein, human

Autor:innen und Institutionen

  • Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China.
  • Department of Prevention and Healthcare, Children's Hospital of Nanjing Medical University, Nanjing, China.
  • Department of Tuberculosis, The Third People's Hospital of Zhenjiang Affiliated to Jiangsu University, Zhenjiang, China.
  • Department of Tuberculosis, The Second People's Hospital of Changshu, Changshu, China.
  • Department of Infectious Disease, The Jurong Hospital Affiliated to Jiangsu University, Jurong, China.
  • Department of Infectious Disease, The People's Hospital of Taixing, Taixing, China.

ORCID-Profile: Shaowen Tang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Cheng, J., Wang, N., Chen, R., Pan, H., Lu, L., Zhang, M., He, X., Yi, H., & Tang, S. (2025). Effects of FECH Gene Polymorphisms and Serum Ferrochelatase Levels on Antituberculosis Drug‐Induced Liver Injury in China. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.70034

Vancouver

Cheng J, Wang N, Chen R, Pan H, Lu L, Zhang M, et al. Effects of FECH Gene Polymorphisms and Serum Ferrochelatase Levels on Antituberculosis Drug‐Induced Liver Injury in China. Fundamental & Clinical Pharmacology. 2025. doi:10.1111/fcp.70034

BibTeX
@article{Cheng2025,
  author = {Cheng, Jingru and Wang, Nannan and Chen, Ruina and Pan, Hongqiu and Lu, Lihuan and Zhang, Meiling and He, Xiaomin and Yi, Honggang and Tang, Shaowen},
  title = {Effects of FECH Gene Polymorphisms and Serum Ferrochelatase Levels on Antituberculosis Drug‐Induced Liver Injury in China},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2025},
  doi = {10.1111/fcp.70034}
}
Kostenlos starten →